Germany moves to lower drug prices

Kupferschmidt, Kai
February 2011
CMAJ: Canadian Medical Association Journal;2/8/2011, Vol. 183 Issue 2, pE77
Academic Journal
The article reports on the adoption of a government legislation on drug pricing in Germany entitled "The Act for the Restructuring of the Pharmaceutical Market" on January 1, 2011. According to the author, the law grants pharmaceutical companies to settle drug prices and secure its benefit throughout the first 12 months commercialization so that it will not be included in a reference-pricing scheme. It adds that the adoption of the legislation was hoped to decrease drug costs for Germans.


Related Articles

  • Assessing the Impact of Global Price Interdependencies. Richter, Anke // PharmacoEconomics;2008, Vol. 26 Issue 8, p649 

    Documented launch delays and the ensuing debate over their underlying causes have focused on assessment from the individual country's perspective. Seen in a larger game theoretical framework this may cause problems, because although the countries see an individual game, the pharmaceutical firm...

  • Just roiling along. Tieman, Jeff; Hallam, Kristen // Modern Healthcare;10/23/2000, Vol. 30 Issue 44, p8 

    Reports the reactions of pharmaceutical companies to the regulation of prescription drug prices in Maine. Reasons of pharmaceutical companies for contesting the law; Information on the lawsuit filed by the Pharmaceutical Research and Manufacturers of America.

  • Prescription Drug Brouhaha. Adrianson, Alex W. // Consumers' Research Magazine;Sep2000, Vol. 83 Issue 9, p38 

    Focuses on the reaction of the pharmaceutical industry to the proposed law on drug prices in Maine. Lawsuit filed by the Pharmaceutical Research and Manufacturers of America; Overview of the law.

  • Reforming Spain's pharmaceutical industry. Ruiz, Magdalena // BMJ: British Medical Journal (International Edition);5/6/89, Vol. 298 Issue 6682, p1206 

    Focuses on the reforms in the pharmaceutical industry in Spain. Introduction of a bill for the substitution of a prescribed drug with another with the same composition; Regulation of the production, quality control, distribution of drugs and pricing of drugs; Objectives of the bill.

  • Health care purchasing at risk. Betz, Robert // Health Systems Review;Jan/Feb95, Vol. 28 Issue 1, p21 

    Comments on marketplace and government pressures on pharmaceutical pricing. Effects of prescription drug discounts on consumers, health care providers and insurers; Implications of Section 1555 of the Federal Acquisition Streamlining Act of 1994; Regulation of access to the General Services...

  • AIDS Drugs & the Pharmaceutical Industry: A Need For Reform. Griffin, Mary T. // American Journal of Law & Medicine;1991, Vol. 17 Issue 4, p363 

    The pharmaceutical industry has long enjoyed substantial profits despite increased requirements for drug approval and various attempts to regulate the industry. Drug companies have avoided effective regulation by blaming high prices on the costs of research and development. The search for drugs...

  • Bl and Lilly's Trajenta battle.  // Pharmaceutical Executive;Nov2011, Vol. 31 Issue 11, p36 

    The article discusses the impact of the German pharmaceutical pricing reform program, Arzneimittelmarktneuordnungsgesetz (AMNOG), on new drugs, that motivated pharmaceutical firm Bl and Lilly to decide not to launch the Trajenta drug in Germany.

  • India moves gently to liberalize drug industry. Jayaraman, K.S. // Nature;9/1/1994, Vol. 371 Issue 6492, p8 

    Reports on the Indian government's decision to liberalize the pharmaceutical industry. Lifting of price controls on several drugs; Greater foreign participation; Encouragement of Indian companies to invest in research.

  • Pharmaceutical Industry.  // Economic Review (05318955);Feb2001, Vol. 32 Issue 2, p37 

    Reports the economic development in pharmaceutical industry in Pakistan. Dependence of pharmaceutical industry on the government in terms of prices. Number of pharmaceuticals companies on the list of Karachi Stock Exchange in 1999; Total pretax profit of pharmaceuticals companies.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics